



INNOVANCE Anti-Xa assay

Anticoagulant testing, simplified

Simplify your anticoagulant testing with one streamlined, ready-to-use assay for heparin and DOAC testing.

siemens-healthineers.com/hemostasis

SIEMENS
Healthineers 

One solution for streamlined, ready-to-use anti-Xa testing


To monitor and manage bleeding risks, labs are asked to safeguard anticoagulant therapies such as heparin or direct oral anticoagulants (DOACs) by testing patients for a growing number of agents. This testing often requires significant time from lab staff, as multiple reagents and steps are frequently required to perform testing.

Anticoagulant testing, simplified

The INNOVANCE® Anti-Xa assay* is an automated, chromogenic assay for the quantitative determination of the activity of unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) as well as rivaroxaban and apixaban concentrations in citrated human plasma. By combining heparin and DOAC testing into one simple and easy-to-use assay, the INNOVANCE Anti-Xa assay* streamlines handling, reduces order complexity, and offers labs an economical testing outcome.

Available without the wait

The INNOVANCE Anti-Xa assay* combines truly ready-to-use liquid reagent for heparin and DOAC testing, allowing 24/7 access to rapid and specific testing for anticoagulants. Unlike most other commercially-available solutions, this assay requires no manual preparation or waiting time. These features not only help to control bleeding risk and balance drug dosing to prevent adverse patient outcomes, but accelerate your lab's anticoagulant testing workflow.



Measured with the INNOVANCE Anti-Xa assay* on the BCS XP System.

Secure and precise result interpretation

The INNOVANCE Anti-Xa assay* features a universal calibrator set that employs a single calibration curve for both types of heparin (UFH and LMWH), streamlining result interpretation and eliminating the risk of evaluation on the wrong curve. The universal calibrator set is traceable to the World Health Organization (WHO) standards for UFH and LMWH, helping to ensure that laboratory personnel can confidently and accurately interpret heparin results.

In addition, the INNOVANCE Anti-Xa assay* features two drug-specific standards sets for the DOACs rivaroxaban and apixaban, allowing for accurate measurement of drug concentrations in ng/mL.

**Not available for sale in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements.*

Why accurate DOAC assessment is imperative

Direct oral anticoagulants such as rivaroxaban and apixaban are direct anti-Xa inhibitor drugs that have evolved over time because of their convenient dosing and short half-life. Though the medication usually does not require monitoring, DOAC testing is needed to properly manage individuals with bleeding conditions, emergency situations that require unplanned surgery, and relevant comorbidities (e.g., renal insufficiency).

Why anti-Xa is the better choice for heparin testing


Heparin is a traditional anticoagulant drug and exists in two forms—UFH and LMWH—both of which considerably accelerate the inactivation of coagulation factor Xa by antithrombin. Clinical data shows that monitoring heparin with an anti-Xa assay has several advantages over APTT testing:¹⁻⁵

- A smoother dose-response curve
- More-stable heparin levels during therapy
- Fewer blood samples required
- Fewer dosage adjustments

Robust performance across all parameters

- Broad and consistent assay range of 0.10 to 1.50 IU/mL for UF and LMW heparin
- Single calibration curve for heparin testing that includes five levels for improved accuracy and precision
- Measuring range for DOACs of 20-350 ng/mL, extendable up to 700 ng/mL by sample dilution
- Quantitative measurements of rivaroxaban and apixaban by using drug-specific calibration curves
- Robust assay design that reduces susceptibility to interferences
- High lot-to-lot consistency that helps ensure consistent patient results over time

INNOVANCE Anti-Xa assay* method comparison study with LMWH and UFH samples



Expanding precision medicine through improved diagnostic accuracy in heparin and DOAC testing

Improved outcomes for labs of any size

With its compact and ready-to-use configuration, INNOVANCE Anti-Xa assay* supports improved laboratory outcomes. Applications are available for a wide range of systems, serving the needs of any-sized lab:

- Liquid reagents require no manual preparation or reconstitution, allowing staff to concentrate on high-value tasks
- Combined testing solution reduces handling, material, and ordering complexity for the lab
- Up to 36 tests per reagent vial across all systems, depending on test mix†
- Ready-to-use assay supports timely patient treatment
- Available on multiple platforms, including the BCS® XP and Atellica® COAG 360* Systems from Siemens Healthineers, and the Sysmex® CA-660,‡ CS-2500/5100 and CN-3000/6000* Systems

INNOVANCE Anti-Xa assay* method comparison studies on Sysmex CS-2500 System vs. STA-Liquid Anti-Xa assay on STA Compact Max System

	Number (n)	Correlation Coefficient (r)	Regression Equation	Predicted Bias at		
				30 ng/mL	50 ng/mL	100 ng/mL
Rivaroxaban	102	0.979	$y = 0.945x + 5.136$ ng/mL	3.5 ng/mL	2.4 ng/mL	-0.4 ng/mL
Apixaban	107	0.975	$y = 1.081x - 2.329$ ng/mL	0.1 ng/mL	1.7 ng/mL	5.8 ng/mL

*Not available for sale in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements.

†Test capacity ranges from 22–36 tests. DOAC tests only: 22 tests per vial; heparin tests only: 36 tests per vial.

‡Heparin applications only.

Built on a proven principle: INNOVANCE Anti-Xa assay*

The INNOVANCE Anti-Xa assay* builds on the proven performance of the INNOVANCE Heparin assay. It leverages the same proven components used in the INNOVANCE Heparin assay, but now also includes DOAC testing capabilities. Further, it complements the Siemens Healthineers menu of hemostasis products that deliver the performance your lab needs to overcome the most difficult testing challenges.



Contact your Siemens Healthineers representative today to simplify your anticoagulant testing with the INNOVANCE Anti-Xa assay.*

*Not available for sale in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements.

At Siemens Healthineers, our purpose is to enable healthcare providers to increase value by empowering them on their journey toward expanding precision medicine, transforming care delivery, and improving patient experience, all made possible by digitalizing healthcare.

An estimated 5 million patients globally benefit every day from our innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics, and molecular medicine, as well as digital health and enterprise services.

We are a leading medical technology company with over 120 years of experience and 18,000 patents globally. Through the dedication of more than 50,000 colleagues in 75 countries, we will continue to innovate and shape the future of healthcare.

Atellica, BCS, INNOVANCE, and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. Sysmex is a trademark of Sysmex Corp. All other trademarks and brands are the property of their respective owners.

Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.

This brochure is intended for use outside the U.S. (OUS) only. Display or promotion to U.S. audiences is prohibited.

References:

1. Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. *Pharmacotherapy*. 2012;32(6):546-58.
2. Vandiver JW, Vondracek TG. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring. *Hosp Pract*. 2013;41(2):16-24.
3. Liveris A, Bello RA, Friedmann P, Duffy MA, Manwani D, Killinger JS, Rodriguez D, Weinstein S. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation. *Pediatr Crit Care Med*. 2014;15(2):e72-9.
4. Adatya S, Uriel N, Yarmohammadi H, Holley CT, Feng A, Roy SS, Reding MT, John R, Eckman P, Zantek ND. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support. *JACC Heart Fail*. 2015;3(4):314-22.
5. van Roessel S, Middeldorp S, Cheung YW, Zwinderman AH, de Pont AC. Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin. *Neth J Med*. 2014;72(6):305-10. Free access: <http://www.njmonline.nl/getpdf.php?id=1463>

Siemens Healthineers Headquarters

Siemens Healthcare GmbH
Henkestr. 127
91052 Erlangen, Germany
Phone: +49 9131 84-0
siemens-healthineers.com

Published by

Siemens Healthcare Diagnostics Inc.
Laboratory Diagnostics
511 Benedict Avenue
Tarrytown, NY 10591-5005
USA
Phone: +1 914-631-8000